Page 6 - Jane Lowe News Today

Lonza to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art...

Lonza to manufacture drug substance for clinical supply of HaemaLogiXs lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-ar...

/PRNewswire/ -- HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and...

Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN) HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in manufacturing monoclonal antibodies BASEL, Switzerland and SYDNEY, Jan. 28, 2022 /PRNewswire/ -- HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel...

SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is please...

SYDNEY, Jan. 25, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased...

On occasion, we love planning extended trips (3 to 10 days) across Arizona to explore a large variety of sites. For some reason or another, our neighbors always seem to

For personal use only ASX RELEASE 3 December 2021 KAZIA ANNOUNCES POSITIVE... | December 2, 2021